Black patients with cancer are significantly more likely to experience cardiotoxicity and congestive heart failure related to chemotherapy than White cancer patients are, a research review indicates. ...

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human ...

Scholastic Achievements of Childhood Leukemia Patients: A Nationwide, Register-Based Study The design and efficacy of the major adjuvant trastuzumab trials was assessed, including the National ...

A new meta-analysis published in OMICS: A Journal of Integrative Biology helps shed light on how changes in mitochondria-related gene expression may cause the cardiotoxicity associated with the cancer ...

CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less likely ...

BARCELONA — Cardiovascular disease risk factors, as well as established disease, in patients undergoing cancer therapy can be safely managed to minimize cancer therapy-related cardiovascular toxicity ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS. At the ASPC 2025 Congress ...

In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...

The recently published meta-analysis by Nissen and Wolski, 1 which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an ...